TCT 2018 | PADN-5: Pulmonary Artery Denervation in Pre- and Post-Capillary Pulmonary Hypertension

This work included 98 patients with pre- and post-capillary pulmonary hypertension defined as mean pulmonary arterial pressures ≥25 mmHg, pulmonary capillary wedge pressures >15 mmHg, and pulmonary vascular resistance >3.0 Wood units. These subjects were randomized to pulmonary artery denervation vs. sildenafil plus sham pulmonary artery denervation. The medical treatment for heart failure was administered to all patients.

TCT 2018 | PADN-5: Denervación pulmonar en hipertensión pulmonar combinada pre y post capilarThe primary endpoint was a 6-minute walk distance test at 6 months, and the secondary endpoint was modification of pulmonary vascular resistance.

 

At 6 months, the 6-minute walk distance test increased by an average of 83 m in the denervation group vs. 15 m in the sildenafil group (p < 0.001). Additionally, pulmonary vascular resistance was significantly lower. Clinical worsening was less frequent among patients in the pulmonary artery denervation group compared with the sildenafil group (16.7% vs. 40%; p = 0.014).

 

Original title: A Randomized Trial of Pulmonary Artery Denervation in Patients with Combined Pre- and Post-Capillary Pulmonary Hypertension.

Presenter: Shao-Liang Chen.

 

padn-5-presentacion

PADN-5-artículo-original


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...